ProCE Banner Activity

CE / CME

Pharmacy-Based HCV Screening and Care: In-Depth Application

Case Challenge
Multimedia
This interactive video module provides in-depth expert perspectives on optimizing HCV service provision in pharmacy settings with an emphasis on screening, linkage to care, key features of HCV treatment, and the importance of drug-drug interaction assessment.

Pharmacists : 1.25 contact {hours} ({0.125} CEUs)

Physicians : maximum of 1.25 AMA PRA Category 1 {Credits}

Released: February 01, 2019

Expiration: January 31, 2020

No longer available for credit.

Share

Faculty

John Faragon

John Faragon, PharmD, BCPS, AAHIVP

Pharmacist, HIV and HCV Medicine
Albany Medical Center
Regional Pharmacy Director
Northeast/Caribbean AIDS Education and Training Center (AETC)
Albany, New York

Michelle T. Martin

Michelle T. Martin, PharmD, FCCP, BCPS, BCACP

Clinical Pharmacist
University of Illinois Hospital and Health Sciences System
Clinical Associate Professor
University of Illinois at Chicago College of Pharmacy
Chicago, Illinois

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

ViiV Healthcare

Target Audience

This program is intended for US pharmacists and other healthcare providers who care for patients with or at risk of HIV and HCV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply best practices in patient counseling and linkage to care for patients who test positive for HCV antibody
  • Provide appropriate patient counsel on characteristics of different HCV treatment options when dispensing HCV therapy
  • Implement pharmacy-based strategies to support HCV therapy provision, including drug-drug interaction assessment and adherence support

Disclosure

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME/CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director Disclosure

Program Director

John Faragon, PharmD, BCPS, AAHIVP

Pharmacist, HIV and HCV Medicine
Albany Medical Center
Regional Pharmacy Director
Northeast/Caribbean AIDS Education and Training Center (AETC)
Albany, New York

John Faragon, PharmD, BCPS, AAHIVP, has disclosed that he has received fees for non-CME/CE services from AbbVie, Gilead Sciences, Janssen, and Merck.

Faculty Disclosure

Primary Author

Michelle T. Martin, PharmD, FCCP, BCPS, BCACP

Clinical Pharmacist
University of Illinois Hospital and Health Sciences System
Clinical Associate Professor
University of Illinois at Chicago College of Pharmacy
Chicago, Illinois

Michelle T. Martin, PharmD, FCCP, BCPS, BCACP, has disclosed that she has received consulting fees and funds for research support from Gilead Sciences and that she has ownership interest in AbbVie, Gilead Sciences, and Merck.

Staff Disclosure

Staff

Jennifer M. Blanchette, Ph.D.

Clinical Editor
Clinical Care Options, LLC

Jennifer M. Blanchette, PhD, has no real or apparent conflicts of interest to report.

Jenny Schulz, PhD

Associate Managing Editor, Hepatitis
Clinical Care Options, LLC

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.

Instructions for Credit

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

This program is assigned ACPE Universal Activity 0797-9999-19-018-H02-P. This program is designated for up to 1.25 contact hours (0.125 CEUs) of continuing pharmacy education credit.

Type of Activity: Application

For Pharmacists: Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Disclosure of Unlabeled Use

The PIM planners and managers have nothing to disclose.

Charles E. Willis, Director of Continuing Education from the Annenberg Center for Health Sciences at Eisenhower consults for Pfizer, Inc.; Amanda Sewell, MBA, Manager of Continuing Education and Melissa Velasquez, Accreditation Specialist both from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 01, 2019, through January 31, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve pharmacists’ competence in contributing to the prevention and management of HIV and HCV infection.